Advertisement

Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans

  • M. Katashima
  • K. Yamamoto
  • Y. Tokuma
  • T. Hata
  • Y. Sawada
  • T. Iga
Article

Summary

The relationship between plasma concentrations and inhibitory effects on gastric acid secretion by proton pump inhibitors (PPIs) omeprazole (OPZ), lansoprazole (LPZ) and pantoprazole (PPZ), was analyzed using a pharmacokinetic/pharmacodynamic (PK/PD) model in humans. The estimated values of apparent reaction rate constant of PPI and H+, K+-ATPase (K) were 1.34±0.17 (μM−1. h−1), 0.339±0.002 and 0.134±0.006 for OPZ, LPZ and PPZ, respectively. The estimated values of apparent turn-over rate constant of H+, K+-ATPase (k) were 0.0252±0.0019 (h−1), 0.0537±0.0006 and 0.0151±0.0002 for OPZ, LPZ and PPZ, respectively. The apparent dissociation constants of the H+, K+-ATPase-PPI complex (k/K.fp) corrected with plasma free fraction (fp) were about 1 nM for OPZ and LPZ and 2.3 nM for PPZ. Therefore, the potency of the inhibitory effect of PPZ on acid secretion may be slightly weaker than that of OPZ or LPZ. The apparent half lives (In2/k) of the inhibitory effect on acid secretion were 12.9 h for LPZ, <27.5 h for OPZ, and <45.9 h for PPZ, the recovery rate of the inhibitory effect of PPZ on acid secretion was slowest among these PPIs. In conclusion, the relationship between plasma concentrations and inhibitory effects of PPIs on gastric acid secretion could be analyzed by the PK/PD model.

Keywords

Omeprazole lansoprazole pantoprazole pharmacokinetics pharmacodynamics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Colin W.H. (1991): Clinical pharmacology of omeprazole. Clin. Pharmacokinet., 20, 38–49.CrossRefGoogle Scholar
  2. 2.
    McTavish D., Buckley M.M.T., Hell R.C. (1991): Omeprazole. Drugs, 42, 138–170.CrossRefPubMedGoogle Scholar
  3. 3.
    Barradell L.B., Faulds D., McTavish D. (1992): Lansoprazole. Drugs, 44, 225–250.CrossRefPubMedGoogle Scholar
  4. 4.
    Spencer C.M., Faulds D. (1994): Lansoprazole, a reappraisal of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs, 48, 404–430.CrossRefPubMedGoogle Scholar
  5. 5.
    Mears J.M., Kaplan B. (1996): Proton pump inhibitors: new drugs and indications. Am. Fam. Physician, 53, 285–292.PubMedGoogle Scholar
  6. 6.
    Wolfe M.M., Soll A.H. (1988): The physiology of gastric acid secretion. N. Engl. J. Med., 319, 1707–1715.CrossRefPubMedGoogle Scholar
  7. 7.
    Rabon E.C., Reuben M.A. (1990): The mechanism and structure of the gastric H+, K+-ATPase. Annu. Rev. Physiol., 52, 321–344.PubMedGoogle Scholar
  8. 8.
    Nagaya H., Satch H., Kubo K., Maki Y. (1989): Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J. Pharmacol. Exp. Ther., 248, 799–805.PubMedGoogle Scholar
  9. 9.
    Nagaya H., Satoh H., Maki Y. (1990): Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in the isolated canine parietal cells. J. Pharmacol. Exp. Ther., 252, 1289–1295.PubMedGoogle Scholar
  10. 10.
    Sachs G., Wallmark B. (1989): The gastric H+, K+-ATPase: the site of action of omeprazole. Scand. J. Gastroenterol., 24 (Suppl 166), 3–11.CrossRefGoogle Scholar
  11. 11.
    Wallmark B. (1989): Omeprazole: mode of action and effect on acid secretion in animals. Scand. J. Gastroenterol., 24 (Suppl 166), 12–17.CrossRefGoogle Scholar
  12. 12.
    Shin J.M., Besancon M., Simon A., Sachs G. (1993): The site of action of pantoprazole in the gastric H+/K+-ATPase. Biochim. Biophys. Acta, 1148, 223–233.CrossRefPubMedGoogle Scholar
  13. 13.
    Cederberg G., Ekenved G., Lind T., Olbe L. (1985): Acid inhibitory characteristics of omeprazole in man. Scand. J. Gastroenterol., 20 (Suppl 108), 105–112.Google Scholar
  14. 14.
    Larsson H., Carlsson E., Junggren U. et al. (1983): Inhibition of gastric acid secretion by omeprazole in the dog and rat. Gastroenterology, 85, 900–907.PubMedGoogle Scholar
  15. 15.
    Lind T., Cederberg G., Ekenved G., Haglund U., Olbe L. (1983): Effect of omeprazole — a gastric proton pump inhibitor — on pentagastrin stimulated acid secretion in man. Gut, 24, 270–276.CrossRefPubMedGoogle Scholar
  16. 16.
    Tateno M., Nakamura N. (1991): Phase I study of lansoprazole (AG-1749) antiulcer agent — capsule form. Rinsho Iyaku, 7, 51–62.Google Scholar
  17. 17.
    Lind T., Cederberg C., Ekenved G., Haglund U., Olbe L. (1983): Effect of omeprazole — a gastric proton pump inhibitor — on pentagastrin stimulated acid secretion in man. Gut, 24, 270–276.CrossRefPubMedGoogle Scholar
  18. 18.
    Cederberg C., Lind T., Röhss K., Olbe L. (1992): Comparison of once-daily intravenous and oral omeprazole on pentagastrin-stimulated acid secretion in duodenal ulcer patients. Digestion, 53, 171–178.CrossRefPubMedGoogle Scholar
  19. 19.
    Katashima M., Yamamoto K., Sugiura M., Sawada Y., Iga T. (1995): Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. Drug Metab. Dispos., 23, 718–723.PubMedGoogle Scholar
  20. 20.
    Simon B., Müller P., Marinis E. et al. (1990): Effect of repeated oral administration of BY 1023/SK&F 96022 — a new substituted benzimidazole derivative — on pentagastrinstimulated gastric acid secretion and pharmacokinetics in man. Aliment. Pharmacol. Ther., 4, 373–379.CrossRefPubMedGoogle Scholar
  21. 21.
    Simon B., Müller P., Hartmann M. et al. (1990): Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K+-ATPase-inhibitor pantoprazole (BY 1023/SK&F 96022) in healthy volunteers. Z. Gastroenterol., 28, 443–447.PubMedGoogle Scholar
  22. 22.
    Anderson T., Andén K., Cederberg C., Lagerström P.O., Lundborg P., Skånberg I. (1990): Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br. J. Clin. Pharmacol., 29, 557–563.Google Scholar
  23. 23.
    Anderson T. (1996): Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Clin Pharmacokinet., 31, 9–28.CrossRefGoogle Scholar
  24. 24.
    Benet L.Z., Zech K. (1994): Pharmacokinetics — a relevant factor for the choice of a drug? Aliment: Pharmacol. Ther., 8, 25–32.Google Scholar
  25. 25.
    Miwa K., Mitani M., Tsukamoto T. et al. (1990): Jpn. Pharmacol. Ther., 18, 3413–3435.Google Scholar
  26. 26.
    Sachs G., Shin J.M. (1995): The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu. Rev. Pharmacol. Toxicol., 35, 277–305.CrossRefPubMedGoogle Scholar
  27. 27.
    Simon W.A., Sturm E., Kohl B. (1988): Inhibition of (H+, K+)-ATPase by 2-((2-pyridyl-methyl)-sulphinyl)-benzimidazoles: improved pH selectivity of dialkoxypyridyl-derivatives. Gastroenterol. Int., 1 (Suppl. 1), 1157.Google Scholar
  28. 28.
    Beil W., Staar U., Sewing K-Fr. (1992): Pantoprazole: a novel H+/K+-ATPase inhibitor with an improved pH stability. Eur. J. Pharmacol., 218, 265–271.CrossRefPubMedGoogle Scholar
  29. 29.
    Besancon M., Shin J.M., Mercier F. et al. (1993): Membrane topology and omeprazole labeling of the gastric H+, K+-adenosinetriphosphatase. Biochemistry, 32, 2345–2355.CrossRefPubMedGoogle Scholar
  30. 30.
    Sachs G., Shin J.M., Besancon M., Prinz C. (1993): The continuing development of acid pump inhibitors. Aliment. Pharmacol. Ther., 7, 4–12.CrossRefPubMedGoogle Scholar
  31. 31.
    Satoh H., Inatomi N., Nagaya H. et al. (1989): Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J. Pharmacol. Exp. Ther., 248, 806–815.PubMedGoogle Scholar
  32. 32.
    Kromer W., Postius S., Riedel R. et al. (1990): BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions. J. Pharmacol. Exp. Ther., 254, 129–135.PubMedGoogle Scholar
  33. 33.
    Bliesath H., Simon B., Hartmann M. et al. (1992): Reduction of pentagastrin stimulated acid output: a suitable method to predict efficacy of an irreversible proton pump inhibitor in peptic ulcer disease. Int. J. Clin. Pharmacol. Ther. Toxicol., 30, 439.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • M. Katashima
    • 3
  • K. Yamamoto
    • 1
  • Y. Tokuma
    • 3
  • T. Hata
    • 3
  • Y. Sawada
    • 2
  • T. Iga
    • 1
  1. 1.Department of PharmacyThe University of Tokyo Hospital, Faculty of Medicine, The University of TokyoTokyoJapan
  2. 2.Faculty of Pharmaceutical SciencesKyushu UniversityKyushuJapan
  3. 3.Biopharmaceutical and Pharmacokinetic Research LaboratoriesFujisawa Pharmaceutical Co. LtdYodogawa-ku, OsakaJapan

Personalised recommendations